SBFMSunshine Biopharma, Inc.

$6M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$6M+3599.8% YoY

Gross Profit

$2M35.1% margin

Operating Income

-$1M-18.2% margin

Net Income

-$902,000-16.2% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

+13.6%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$28M

Total Liabilities

$5M

Stockholders' Equity

$23M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$150,307	+3599.8%
Gross Profit	$2M	$75,624	+2482.5%
Operating Income	-$1M	-$695,796	-45.7%
Net Income	-$902,000	-$538,872	-67.4%

SBFM Q2 2023 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena